Sanofi Sees China Growth Bolstered By County Hospitals Push
This article was originally published in The Pink Sheet Daily
Executive Summary
Thousands of county hospitals offer significant growth opportunities for the next 10 years, says Sanofi SVP Jean-Luc Lowinski, but adds the challenges at building the market are unique for multinational drug manufacturers in China.
You may also be interested in...
Pfizer Teams With Distributor Jointown To Delve Deeper Into China's Rural Markets
SHANGHAI - Pfizer Inc., like many of its Big Pharma peers is seeking out local Chinese partners to gain access to China's lower-tier cities and rural areas. To that end, the world's largest pharma company recently signed an agreement with China's third-largest pharma distributor Jointown Pharmaceutical Group Co., Ltd. to distribute Pfizer products in markets outside of big cities
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.